IPIX — Innovation Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review
Brief: Innovation Pharmaceuticals Announces Publication Of Peer-Reviewed Scientific Article In Journal Viruses On Anti-Sars-Cov-2 Properties Of Brilacidin
Brief: Innovation Pharma Provides Study Details For Ongoing Phase 2 Clinical Trial Of Brilacidin In Hospitalized Covid-19 Patients
Brief: Innovation's Phase 2 Clinical Trial Of Brilacidin For Treating COVID-19 To Begin Next Week
Brief: FDA Grants IND Approval For Phase 2 Clinical Trial Of Innovation Pharmaceuticals’ Brilacidin To Treat COVID-19
Brief: Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For Covid-19 Clinical Study
Brief: Innovation Pharmaceuticals Announces Pre-Ind Meeting Request Granted By FDA For The Study Of Brilacidin For The Treatment Of Covid-19
Brief: Innovation Reports Data From Lab Supporting Brilacidin As Potential Treatment For SARS-CoV-2
Brief: Innovation Pharma Says Covid-19 Drug Candidate Achieves Selectivity Index Exhibiting Potent Anti-Sars-Cov-2 Activity
Brief: Innovation Says Collaborating With Regional Biocontainment Lab On Grant Application To Research Brilacidin As Pan-Coronavirus Therapeutic
Brief: Innovation Pharmaceuticals Receives Data Showing Brilacidin Inhibits Sars-Cov-2 (Covid-19) In A Human Cell Line
Brief: Innovation Pharmas' Brilacidin Reduces Viral Titer Of Sars-Cov-2 (Covid-19) By 75% After Only 1 Hour Of Preincubation In In Vitro Study At Bsl-3 Facility
Brief: Innovation Pharma In Discussions To Advance Brilacidin Into Human Trials Against Covid-19
Brief: Innovation Pharmaceuticals Brilacidin Received By U.S. Regional Biocontainment Laboratory Testing Against Coronavirus
Brief: Innovation Pharmaceuticals Signs Second MTA To Explore Brilacidin As Coronavirus Covid-19 Treatment
Brief: Innovation Pharmaceuticals Plans For Mid-Stage Trial Of New Treatment For Ulcerative Colitis